Application and Prospective of CRISPR-Cas in Cancer Diagnosis and Therapy

Xiaoshu Li

doi:10.62051/03s9qv72

Authors

Xiaoshu Li

DOI:

https://doi.org/10.62051/03s9qv72

Keywords:

Cancer diagnosis; Cancer treatment; CRISPR‐Cas; Genome editing.

Abstract

Cancer, a leading cause of mortality worldwide, poses a significant challenge to public health. The advent of CRISPR-Cas systems has introduced a novel and promising approach to overcoming the limitations of conventional cancer therapies. This review delves into the burgeoning role of CRISPR-Cas in the oncology field, highlighting its utility in both cancer diagnosis and therapy. In the diagnostic realm, CRISPR-based technologies, such as DETECTR and SHERLOCK, leverage the non-specific collateral cleavage activity of Cas12 and Cas13 proteins for highly sensitive detection of nucleic acid sequences, offering rapid and sensitive diagnostic capabilities. Therapeutically, CRISPR-Cas systems inactivate oncogenes and enhance treatment outcomes through engineered variants and innovative approaches. Variants such as nCas9 and dCas9 have been engineered to enhance specificity and transcriptional regulation, respectively. Challenges including the need for high specificity to avoid off-target effects, long-term safety assessments and ethical considerations persist, yet ongoing research aims to refine these technologies for enhanced efficacy and safety. Overall, CRISPR-Cas systems herald a new era in precision medicine for cancer patients.

Downloads

Download data is not yet available.

References

[1] M. Cao, H. Li, D. Sun, S. He, X. Yan, F. Yang, S. Zhang, C. Xia, L. Lei, J. Peng, W. Chen, Current cancer burden in China: epidemiology, etiology, and prevention, Cancer Biology & Medicine 19 (2022) 1121–1138.

[2] R.L. Siegel, A.N. Giaquinto, A. Jemal, Cancer statistics, 2024, CA Cancer J Clin 74 (2024) 12–49.

[3] G. Behrouzian Fard, M.H. Ahmadi, M. Gholamin, R. Amirfakhrian, E. Saberi Teimourian, M.A. Karimi, M. Hosseini Bafghi, CRISPR-Cas9 technology: As an efficient genome modification tool in the cancer diagnosis and treatment, Biotechnology and Bioengineering 121 (2024) 472–488.

[4] C.-Y. Zhao, R. Cheng, Z. Yang, Z.-M. Tian, Nanotechnology for Cancer Therapy Based on Chemotherapy, Molecules 23 (2018) 826.

[5] G. Wei, Y. Wang, G. Yang, Y. Wang, R. Ju, Recent progress in nanomedicine for enhanced cancer chemotherapy, Theranostics 11 (2021) 6370–6392.

[6] K. Esfahani, L. Roudaia, N. Buhlaiga, S.V. Del Rincon, N. Papneja, W.H. Miller, A Review of Cancer Immunotherapy: From the Past, to the Present, to the Future, Current Oncology 27 (2020) 87–97.

[7] A. Katti, B.J. Diaz, C.M. Caragine, N.E. Sanjana, L.E. Dow, CRISPR in cancer biology and therapy, Nat Rev Cancer 22 (2022) 259–279.

[8] Y. Xu, Z. Li, CRISPR-Cas systems: Overview, innovations and applications in human disease research and gene therapy, Comput Struct Biotechnol J 18 (2020) 2401–2415.

[9] H.-X. Wang, M. Li, C.M. Lee, S. Chakraborty, H.-W. Kim, G. Bao, K.W. Leong, CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery, Chem. Rev. 117 (2017) 9874–9906.

[10] L. Yi, J. Li, CRISPR-Cas9 therapeutics in cancer: promising strategies and present challenges, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1866 (2016) 197–207.

[11] X. Yang, B. Zhang, A review on CRISPR/Cas: a versatile tool for cancer screening, diagnosis, and clinic treatment, Funct Integr Genomics 23 (2023) 182.

[12] K. Balon, A. Sheriff, J. Jacków, Ł. Łaczmański, Targeting Cancer with CRISPR/Cas9-Based Therapy, Int J Mol Sci 23 (2022) 573.

[13] Tebas Pablo, Stein David, Tang Winson W., Frank Ian, Wang Shelley Q., Lee Gary, Spratt S. Kaye, Surosky Richard T., Giedlin Martin A., Nichol Geoff, Holmes Michael C., Gregory Philip D., Ando Dale G., Kalos Michael, Collman Ronald G., Binder-Scholl Gwendolyn, Plesa Gabriela, Hwang Wei-Ting, Levine Bruce L., June Carl H., Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV, New England Journal of Medicine 370 (2014) 901–910.

[14] Frangoul Haydar, Altshuler David, Cappellini M. Domenica, Chen Yi-Shan, Domm Jennifer, Eustace Brenda K., Foell Juergen, de la Fuente Josu, Grupp Stephan, Handgretinger Rupert, Ho Tony W., Kattamis Antonis, Kernytsky Andrew, Lekstrom-Himes Julie, Li Amanda M., Locatelli Franco, Mapara Markus Y., de Montalembert Mariane, Rondelli Damiano, Sharma Akshay, Sheth Sujit, Soni Sandeep, Steinberg Martin H., Wall Donna, Yen Angela, Corbacioglu Selim, CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia, New England Journal of Medicine 384 (2021) 252–260.

[15] J.P.K. Bravo, T. Hallmark, B. Naegle, C.L. Beisel, R.N. Jackson, D.W. Taylor, RNA targeting unleashes indiscriminate nuclease activity of CRISPR–Cas12a2, Nature 613 (2023) 582–587.

[16] O. Piepenburg, C.H. Williams, D.L. Stemple, N.A. Armes, DNA Detection Using Recombination Proteins, PLoS Biol 4 (2006) e204.

[17] M.M. Kaminski, O.O. Abudayyeh, J.S. Gootenberg, F. Zhang, J.J. Collins, CRISPR-based diagnostics, Nat Biomed Eng 5 (2021) 643–656.

[18] S. Kim, S. Ji, H.R. Koh, CRISPR as a Diagnostic Tool, Biomolecules 11 (2021) 1162.

[19] M. Wang, M. Chen, X. Wu, X. Huang, B. Yu, CRISPR applications in cancer diagnosis and treatment, Cell Mol Biol Lett 28 (2023) 73.